NCT05169658 - Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

April 2, 2025

Study Completion Date

April 2, 2025

Conditions

Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions

BIOLOGICAL

Mosunetuzumab

Given SC

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Polatuzumab Vedotin

Given IV

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG-PET and FDG-PET/CT

PROCEDURE

Computed Tomography

Undergo CT and FDG-PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT and FDG-PET/CT

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle